Vav3-Rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence

NCUIR > college of Health Sciences and Technology > Department of Life Science > journal & Dissertation > Item 987654321/102655

Please use this identifier to cite or link to this item: https://ir.lib.ncu.edu.tw/handle/987654321/102655

Title:	Vav3-Rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence
Authors:	王陸海;Lin, Kai-Ti;Gong, Jianli;Li, Chien-Feng;Jang, Te-Hsuan;Chen, Wen-Ling;Chen, Huei-Jane;Wang, Lu-Hai
Contributors:	生醫理工學院生命科學系
Date:	2012-06-15
Issue Date:	2026-04-23 11:14:21 (UTC+8)
Publisher:	American Association for Cancer Research Inc.;American Association for Cancer Research (AACR)
Abstract:	摘要： AbstractProstate cancer remains the second leading cause of cancer death in men in the Western world. Yet current therapies do not significantly improve the long-term survival of patients with distant metastasis. In this study, we investigated the role of the guanine nucleotide exchange factor Vav3 in prostate cancer progression and metastasis and found that Vav3 expression correlated positively with prostate cancer cell migration and invasion. Stimulation of the receptor tyrosine kinase EphA2 by ephrinA1 resulted in recruitment and tyrosine phosphorylation of Vav3, leading to Rac1 activation as well as increased migration and invasion in vitro. Reduction of Vav3 resulted in fewer para-aortic lymph nodes and bone metastasis in vivo. Clinically, expression of Vav3 and EphA2 was elevated in late-stage and metastatic prostate cancers. Among patients with stage IIB or earlier prostate cancer, higher Vav3 expression correlated with lower cumulative biochemical failure-free survival, suggesting that Vav3 may represent a prognostic marker for posttreatment recurrence of prostate cancer. Together, our findings provide evidence that the Vav3-mediated signaling pathway may serve as a therapeutic target for prostate cancer metastasis. Cancer Res; 72(12); 3000–9. ©2012 AACR. 出版者： American Association for Cancer Research (AACR) 出版日期： 2012-06-14 出處： Cancer Research, 2012-06, Vol.72 (12), p.3000-3009 識別號： ISSN: 0008-5472 識別號： DOI: 10.1158/0008-5472.can-11-2502
Appears in Collections:	[Department of Life Science] journal & Dissertation

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	39	View/Open

社群 sharing

Loading...